The state of New York currently has 49 active clinical trials seeking participants for Depression research studies. These trials are conducted in various cities, including New York, Rochester, Bronx and Buffalo.
A Prospective, Multi-center, Randomized Controlled Blinded Trial Demonstrating the Safety and Effectiveness of VNS Therapy® System as Adjunctive Therapy Versus a No Stimulation Control in Subjects With Treatment-Resistant Depression
Recruiting
Objectives of this study are to determine whether active VNS Therapy treatment is superior to a no stimulation control in producing a reduction in baseline depressive symptom severity, based on multiple depression scale assessment tools at 12 months from randomization.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/11/2024
Locations: Dent Neurological Institute, Amherst, New York +7 locations
Conditions: Treatment Resistant Depression
Virtual Neuro-Navigation System for Personalized Community Based TMS
Recruiting
Phase I study of a virtual neuro-navigation package with built-in support for identifying specific "surface-based" targets to optimze TMS treatment.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: Columbia Docs, New York, New York
Conditions: Treatment Resistant Depression
Development of Neuro-Navigated Transcranial Magnetic Stimulation (TMS) Using MRI
Recruiting
Healthy controls (HC) will be studied once to provide data needed to validate the virtual neuro-navigation system. All subjects will undergo a single MRI session and will then participate in an on-line neuro-navigation session in which various TMS coil positions will be recorded. The brain/head images will be provided to the programmer to permit development of the virtual neuro-navigation algorithm. Data from Yr1 will be used by the programmer as a training sample, and from Yr2 as a test sample.
Gender:
All
Ages:
Between 18 years and 60 years
Trial Updated:
02/28/2024
Locations: Columbia University Irving Medical Center, New York, New York
Conditions: Treatment Resistant Depression
A Study to Assess the Efficacy and Safety of REL-1017 as Adjunctive Treatment for Major Depressive Disorder (MDD)
Recruiting
This is an outpatient, 2-arm, Phase 3, multicenter, randomized, double-blind, placebo-controlled study to assess the efficacy and safety of REL-1017 once daily (QD) as an adjunctive treatment of Major Depressive Disorder. Study participants will continue to take their current antidepressant therapy in addition to the study drug or placebo for the duration of the treatment period.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Cedarhurst, New York +2 locations
Conditions: Major Depressive Disorder, Depression
Randomized, Double-Blind, Placebo-Controlled Trial of REL-1017 as Adjunctive Treatment for MDD
Recruiting
A Phase 3, randomized, double-blind, placebo-controlled, multicenter trial of REL-1017 in patients with major depressive disorder (MDD).
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
02/15/2024
Locations: Relmada Site, Brooklyn, New York +2 locations
Conditions: Major Depressive Disorder, Depression
Engagement in CHildhood-Onset Systemic Lupus
Recruiting
The goal of this observational and pilot study is to better understand how depression symptoms may contribute to how well adolescent and young adults with lupus follow-up with their lupus clinical care. The main questions it aims to answer are: Whether anhedonia (a core symptom of depression) predicts disengagement in care Whether a patient-tailored mobile health application built to improve both engagement in care and depression symptoms will be feasible and acceptable to adolescents and young... Read More
Gender:
All
Ages:
Between 15 years and 24 years
Trial Updated:
02/08/2024
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Lupus Erythematosus, Systemic, Depression
IGC-AD1 Trial on Agitation in Dementia Due to Alzheimer's
Recruiting
The purpose of this study is to assess the efficacy of an oral medication, IGC-AD1 that is a natural THC-based (Tetrahydrocannabinol) formulation, administered in micro doses, twice a day, on symptomatological Agitation, in patients with mild to severe dementia from Alzheimer's.
Gender:
All
Ages:
60 years and above
Trial Updated:
01/05/2024
Locations: Site 900, Amherst, New York
Conditions: Alzheimer Disease, Agitation,Psychomotor, Depression, Anxiety, Memory Impairment, Care Giving Burden, NPS, Agitated; State, Acute Reaction to Stress, Aggression, Aggressive Outburst
WellPATH-PREVENT: A Mobile Intervention for Middle-Aged and Older Adults Hospitalized for Suicidal Ideation or Attempt
Recruiting
The goal of this project is to test whether WellPATH-PREVENT (a novel, mobile psychosocial intervention) improves a specific aspect of emotion regulation, i.e., cognitive reappraisal ability, and reduces suicide risk in middle-aged and older adults (50-90 years old) who have been discharged after a suicide-related hospitalization (i.e. for suicidal ideation or suicide attempt).
Gender:
All
Ages:
Between 50 years and 90 years
Trial Updated:
12/19/2023
Locations: New York Presbyterian Hospital/Weill Cornell Medicine, New York, New York +1 locations
Conditions: Suicide, Attempted, Suicidal Ideation, Depression
Mobile Cognitive Behavioral Therapy for Medical and Graduate Students
Recruiting
The study aims to assess and compare clinician-delivered cognitive behavior therapy (CBT) supplemented with "MAYA", a mobile cognitive behavioral therapy app program to clinician-delivered cognitive behavioral therapy alone. The experimental group will be asked to use the mobile application at least two times per week for six weeks, for at least 20 minutes on each of the two days in addition to the clinician-delivered CBT. Participants will complete a weekly self-report assessment battery design... Read More
Gender:
All
Ages:
Between 18 years and 40 years
Trial Updated:
12/11/2023
Locations: Weill Cornell Medical College, New York, New York
Conditions: Anxiety Disorders, Depression
Psychiatric Outcomes of Unruptured Intracranial Aneurysms (POUIA)
Recruiting
The impact of cerebrovascular procedures on patients experiencing anxiety and depression is not well studied despite the high prevalence of these mental health disorders. Unruptured Intracranial aneurysms (UIAs) have a prevalence of approximately 3% and an annual risk of 1-2% in the general population. Despite the high risk of fatality following aneurysm rupture with a rate of 40-50%, the overall aneurysm growth and rupture risks are rare (less than 3% per aneurysm per year) and many patients ca... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
12/04/2023
Locations: Montefiore Medical Center, Bronx, New York
Conditions: Anxiety Depression, Aneurysm Cerebral, Mental Health Wellness 1
Trajectories of Recovery After Intravenous Propofol Versus Inhaled VolatilE Anesthesia Trial
Recruiting
The investigators will conduct a 12,500-patient randomized multi-center trial to determine (i) which general anesthesia technique yields superior patient recovery experiences in any of three surgical categories ((a) major inpatient surgery, (b) minor inpatient surgery, (c) outpatient surgery) and (ii) whether TIVA confers no more than a small (0.2 %) increased risk of intraoperative awareness than INVA in patients undergoing both outpatient and inpatient surgeries
Gender:
All
Ages:
18 years and above
Trial Updated:
11/22/2023
Locations: Weill Cornell Medicine, New York, New York
Conditions: Surgery-Complications, Anesthesia Complication, Anesthesia Awareness, Anesthesia, Surgery, Quality of Life, Pain, Postoperative, Anesthesia Morbidity, Depression, Sleep Disorders, Circadian Rhythm
Brief Interventions for Coping With Distress
Recruiting
This study is being done to compare the effectiveness of three different skills trainings to cope with distress. These three trainings are: 1) an attention skills training, 2) an attention and reflective thought skills training, and 3) a health and wellness education training.
Gender:
All
Ages:
Between 18 years and 65 years
Trial Updated:
11/21/2023
Locations: Teachers College, Columbia University, New York, New York
Conditions: Distress, Emotional, Emotional Dysfunction, Anxiety, Depression